Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

REGISTER for free or LOG IN to view this content

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Clinical Cardiology

Clinical Pharma

Lipids

Presentation

AHA 2018

Up Next

Presentation AHA 2018

High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Presenter: Gregory Piazza

November 11, 2018

More slides +

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Presentation AHA 2018

REGROUP Trial: A Prospective, Randomized TRial Comparing Endoscopic vs. Open Vein Grafts in CABG Surgery

Presenter: Marco A. Zenati

November 13, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.